Low-Molecular Compounds Stimulating the Recovery of Nervous, Bone, and
Epithelial Tissues
Every year, millions of
surgeries result in tissue injuries, often leading to complications and an
increased risk of disability. Developing new medications capable of stimulating
the regeneration of nervous, bone, and epithelial tissues is crucial for
improving patients' quality of life, accelerating recovery from injuries, and
enhancing treatment effectiveness. The creation of drugs that stimulate damaged
tissue recovery opens up prospects for minimizing complications and speeding up
patient rehabilitation.
Currently, there are virtually no
universal drugs in clinical practice that stimulate tissue recovery
after injuries. Studies show that certain low-molecular compounds, due to their
low toxicity and high therapeutic activity, stimulate the synthesis of nucleic
acids and proteins, activate cell division, and enhance the immune response.
These properties make them promising candidates for the development of modern
tissue regeneration accelerators.
The implantation of neurochips
opens new horizons in medicine and neurotechnologies
but can damage the myelin sheath of nerve fibers, disrupting the transmission
of nerve impulses. Using compounds that facilitate the restoration of the
myelin sheath is a key factor for the successful integration of neuroimplants and the recovery of nervous system functions
after intervention.
We have synthesized compounds
that have demonstrated their effectiveness in animal tests (rats, rabbits, and
goats). Significant acceleration in wound healing, nerve tissue recovery -
including myelin sheath regeneration - and bone tissue regeneration during
osteocyte growth has been observed. The mechanisms of
the studied compounds' effects on cells at the site of damage have been identified.
The introduction of new
repair agents into medical practice will provide opportunities for treating
complex injuries, chronic wounds, and degenerative diseases. Future studies are aimed at optimizing composition, developing drug
formulations, and conducting clinical trials. We are also exploring the
possibility of creating combined drugs that enhance tissue regeneration through
the synergy of various active ingredients.
We invite research teams,
pharmaceutical companies, and medical institutions to collaborate in the
development and implementation of innovative regenerative medications.
Together, we can ensure the availability of new tissue recovery technologies
for patients worldwide. Contact us to discuss collaboration opportunities.
1. Composition For
Stimulation Of Reparative Regeneration Of Epithelial, Nerve And Bone Tissues
Yurij I. Murinov,
Natalia
N. Kabal'nova, Stanislav A. Grabovskij,
Ivan S. Raginov, Lenar R. Valiullin, Vladislav I. Egorov /
Patent RU2677327 (2018).
2. In vitro
proliferative activity of 6-substituted uracil derivatives. Stanislav A. Grabovskiy, Natalia N. Kabal'nova, Nadezhda M. Andriayshina, et. al. / Journal Of Pharmacy & Pharmacognosy Research, 2021, 9(3), 357-365.
3.
The Impact of 5-Substituted Uracil Derivatives on Immortalized Embryo Lung
Cells. Natalia N. Kabal'nova, Stanislav A. Grabovskiy, Nadezhda
M. Andriayshina, et. al. / Letters in Drug Design & Discovery, 2017,
14(12), 1409-1414. DOI 10.2174/1570180814666170502171640
4.
The Cytoprotective Properties Assessment of
6-Substituted Uracil Derivatives Under the Influence of Deltamethrin
on Rat Gasser's Ganglion Neurinoma Cell (RGGN-1) Vladislav I. Egorov, Lenar R. Valiullin, Ilgiz I. Idiyatov, Vadim V. Biryulya, Stanislav A. Grabovskiy, Ivan S. Raginov, Sergey Yu. Smolentsev, Konstantin
Kh. Papunidi / Research Journal of Pharmaceutical,
Biological and Chemical Sciences, 2018, 9(3), 569-574. WOS:000438847100070